Daunorubicin is used for: Acute leukaemia; AIDS-related Kaposi's sarcoma.
Recorded in the NepalDoc medicine catalog for Daunorubicin.
Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
From the U.S. FDA-approved label for Daunorubicin. Full label: DailyMed.
Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
From the U.S. FDA-approved label for Daunorubicin. Full label: DailyMed.
Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit. Principles In order to eradicate the leukemic cells and induce a complete remission, a profound suppression of the bone marrow is usually required. Evaluation of both the peripheral blood and bone marrow is mandatory in the formulation of appropriate treatment plans.
Directions from the U.S. FDA-approved label for Daunorubicin — your doctor or pharmacist may advise differently.
Daunorubicin hydrochloride injection is contraindicated in patients who have shown a hypersensitivity to it.
Excerpt from the U.S. FDA-approved label for Daunorubicin. Talk to a pharmacist or doctor before use.
Bone Marrow Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug. Therapy with daunorubicin hydrochloride should not be started in patients with pre-existing drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage. Cardiac Effects Special attention must be given to the potential cardiac toxicity of daunorubicin hydrochloride, particularly in infants and children.
Warnings and precautions excerpt from the U.S. FDA-approved label for Daunorubicin — not a complete list. Talk to a pharmacist or doctor before use.
Dose-limiting toxicity includes myelosuppression and cardiotoxicity (see WARNINGS section). Other reactions include: Cutaneous Reversible alopecia occurs in most patients. Rash, contact dermatitis and urticaria have occurred rarely. Gastrointestinal Acute nausea and vomiting occur but are usually mild. Antiemetic therapy may be of some help. Mucositis may occur 3 to 7 days after administration.
Excerpt from the U.S. FDA-approved label for Daunorubicin — not a complete list. Talk to a pharmacist or doctor about side effects.
2 brands · 2 makers in the NepalDoc catalog — see the full Daunorubicin guide →
What is Daunotec?
Daunotec 20mg Injection is a Daunorubicin medicine made by Cipla Ltd. It comes as 20mg Injection.
What is Daunotec used for?
Daunorubicin is used for Acute leukaemia, AIDS-related Kaposi's sarcoma.
What is the generic name of Daunotec?
The generic name of Daunotec is Daunorubicin.
Which brands of Daunorubicin are available in Nepal?
2 brands of Daunorubicin are listed in the NepalDoc catalog, from 2 makers — including Aunomycin 20mg Injection.
What are the side effects of Daunorubicin?
Dose-limiting toxicity includes myelosuppression and cardiotoxicity (see WARNINGS section). Other reactions include: Cutaneous Reversible alopecia occurs in most patients. Rash, contact dermatitis and urticaria have occurred rarely.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
